Clinical trials: Cirrhosis Liver
Gastric Varices Bleeding, Liver Cirrhoses
Interventional Devascularization Plus HVPG-Guided Carvedilol Therapy vs TIPS
Gastric varices (GV) are present in around 20% of patients with cirrhosis. Bleeding from GV accounts for 10-20% of all variceal bleeding.
- Trial name
- NCT04198259
- Testing
- interventional devascularization, TIPS
- Volunteers
- 212 people
- Sponsor
- Air Force Military Medical University, China
CT Portography Grading of Liver Cirrhosis
CT Portography in Grading of Liver Cirrhosis
Esophageal variceal bleeding and hepatic encephalopathy are serious complications of hepatic cirrhosis, and they may lead to high mortality rate and severely threaten life quality of the patients
- Trial name
- NCT03453580
- Testing
- multislice computed tomography portography
- Volunteers
- 100 people
- Sponsor
- Assiut University
Alcoholic Cirrhosis
SAMe Trial for Patients With Alcoholic Cirrhosis
The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B.
- Trial name
- NCT04250259
- Testing
- SAMe 400 mg tablet
- Where
- 2 sites in United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Indiana University
Primary Biliary Cholangitis
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
- Trial name
- ELSPIRE (NCT06383403)
- Testing
- Elafibranor
- Where
- 60 sites in United States, Czechia and 8 more
- Volunteers
- 92 people
- Sponsor
- Ipsen
Cholestasis, Primary Sclerosing Cholangitis
Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
We wish to develop a protocol for PET/CT examination of humans using the bile acid tracer 11C-cholylsarcosine. This is done by a series of PET/CT examinations of healthy humans and patients with cholestatic disorders.
- Conditions
- Cholestasis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Trial name
- NCT01879735
- Testing
- 11C-CSar, ICG
- Where
- Denmark
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Portal Hypertension
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between the wedged hepatic venous pressure (WHVP)…
- Trial name
- NCT04797910
- Volunteers
- 24 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-Alcoholic Fatty Liver Disease
Omics Techniques in Fatty Liver Disease
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world.
- Trial name
- NCT05907408
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Cirrhosis, Portal Hypertension
Danish Carvedilol Study in Portal Hypertension
Patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding.
- Trial name
- DACAPO (NCT00493480)
- Testing
- carvedilol, propranolol
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Obesity
Evaluation of Liver Fibrosis Following Surgical-induced Weight Loss
Obesity is a frequent disease with an increased prevalence, estimated to 12.4% in France (OBEPI study 2006). Non alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) both complicate morbid obesity and…
- Trial name
- FIBROTEST (NCT01469962)
- Testing
- Surgical procedure
- Where
- France
- Volunteers
- 255 people
- Sponsor
- University Hospital, Rouen
Hepatic Encephalopathy, Cirrhosis, Liver
Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication
Hepatic encephalopathy is the most common complication after TIPS, and hepatic encephalopathy occurs in almost all portosystemic shunts.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver, Portosystemic Shunt
- Trial name
- NCT05128305
- Testing
- traditional Chinese medicine1 and traditional Chinese medicine 2
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Qianfoshan Hospital
Liver Cirrhosis
The Effect of Resistance Training on Muscle Strength and Nutritional Status in Patients With Liver Cirrhosis
The purpose is to investigate the effect of strength training on muscle strength, muscle mass and nutritional status in patients with liver cirrhosis to clarify possible metabolic and inflammatory changes during this…
- Trial name
- NCT02343653
- Testing
- Nutrition and strength training, Nutrition
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- University of Aarhus
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatic Encephalopathy, Liver Cirrhosis
Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
The purpose of this study is to test feasibility of measuring flumazenil-induced changes in cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of hepatic encephalopathy (HE) in subjects with…
- Trial name
- NCT02048969
- Testing
- Flumazenil
- Where
- United States
- Sponsor
- Yale University
Hepatitis C Virus Infection
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV)…
- Trial name
- NCT04112303
- Testing
- SOF/VEL
- Where
- 22 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Gilead Sciences
Primary Biliary Cirrhosis
Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)
The study is aimed to compare the efficacy and tolerability of a combination therapy with ursodeoxycholic acid (12-16 mg/kg body weight (BW)/d) plus budesonide (9 mg/d) vs.
- Trial name
- NCT00746486
- Testing
- budesonide
- Where
- 2 sites in France, Germany
- Volunteers
- 62 people
- Sponsor
- Dr. Falk Pharma GmbH
Liver Fibrosis
Three-Dimensional T1rho Using Spiral Fast Spin Echo
Liver fibrosis is the main feature in early chronic liver diseases. If identified early, liver fibrosis is reversible. The current gold standard for diagnosing liver fibrosis is invasive liver biopsy.
- Trial name
- NCT05154656
- Where
- Hong Kong
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Liver Cirrhosis, Diabetes Mellitus
Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes
The liver plays a crucial role in physiological glycemic control through its involvement in several glucose metabolism processes, including glycogenogenesis and glycogenolysis.
- Trial name
- NCT02325622
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Liver Cirrhoses, Malignant Ascites
International Alfapump Cohort Study
This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.
- Trial name
- TOPMOST (NCT04326946)
- Testing
- Alfapump
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 400 people
- Sponsor
- Sequana Medical N.V.
Esophageal and Gastric Varices, Liver Cirrhosis
Pantoprazole After Prophylactic Endoscopic Variceal Treatment
Traditionally, it is considered that gastric acid delays ulcer healing, and acid suppression can reduce the risk of post-banding ulcer bleeding and promote mucosal healing at the ulcer site.
- Trial name
- NCT07248722
- Testing
- Pantoprazole
- Where
- China
- Volunteers
- 208 people
- Sponsor
- General Hospital of Shenyang Military Region
Porto-Sinusoidal Vascular Disease, Cirrhosis Due to Hepatitis B
TIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal Bleeding
Platinum-based compounds are associated with several adverse effects, including Porto-Sinusoidal Vascular Disease (PSVD). Therapeutic strategies for platinum-related PSVD are based on the management of complications seen in…
- Conditions
- Porto-Sinusoidal Vascular Disease, Cirrhosis Due to Hepatitis B, Esophageal Variceal Rebleeding, Gastric Variceal Bleeding
- Trial name
- NCT06635122
- Testing
- Transjugular intrahepatic portosystemic shunt, Endoscopic treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Air Force Military Medical University, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.